复发和难治性多发性骨髓瘤:新型疗法疗效的系统综述与网络Meta分析
该系统综述与网络Meta分析纳入2002年1月1日至2022年2月28日间37项随机试验、34种复发和/或难治性多发性骨髓瘤(RRMM)治疗方案,以无进展生存期(PFS)相对地塞米松(DEX)的风险比(HR)为主要终点。达雷妥尤单抗联合来那度胺和DEX相比DEX的HR为0.13(95%CI 0.08-0.20),p-score 0.9796,排名最佳。异质性检验I²=41.3%(p=0.146),未见显著异质性证据。
要点
- 达雷妥尤单抗+来那度胺+DEX对比DEX的PFS HR为0.13(95%CI 0.08-0.20),p-score 0.9796,排名最佳。
- 共筛选1136篇摘要,最终纳入37项随机试验,涵盖34种RRMM治疗方案。
- 异质性检验I²=41.3%(p=0.146),未见显著异质性证据。
核心结论
- 本网络Meta分析证实含抗CD38抗体三药方案治疗RRMM具有优异疗效,并为评估嵌合抗原受体T细胞治疗和双特异性T细胞衔接器治疗疗效提供背景数据。
研究设计与样本
- 系统综述与网络Meta分析,检索PubMed、Cochrane和Embase数据库2002年1月1日至2022年2月28日的随机试验,共筛选1136篇摘要,纳入37项研究、34种RRMM治疗方案。
主要发现
- 主要终点为无进展生存期(PFS),以相对地塞米松(DEX)的风险比(HR)及95%置信区间(95%CI)评价,并采用p-score对治疗排序。
- 达雷妥尤单抗联合来那度胺和DEX为RRMM最佳治疗,对比DEX的HR为0.13(95%CI 0.08-0.20),p-score 0.9796。
- 异质性检验I²=41.3%(p=0.146),未见显著异质性证据。
关键数值与推荐
- 达雷妥尤单抗+来那度胺+DEX对比DEX的PFS HR为0.13(95%CI 0.08-0.20),p-score 0.9796。
- 异质性I²=41.3%(p=0.146)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis of multiple myeloma (MM) has dramatically improved with the development of new drugs, and it has become important to determine the appropriate combinations of these novel agents. This study was a systematic review and network meta-analysis (NMA) of randomized trials in patients with relapsed and/or refractory (RR) MM. The PubMed, Cochrane, and Embase databases were searched for randomized trials from 1 January 2002 to 28 February 2022 of patients treated for MM. The primary end-point was progression-free survival (PFS), evaluated as a hazard ratio (HR) with a 95% confidence interval (95% CI) compared to dexamethasone (DEX). The p-score was used to rank treatments. Of a total of 1136 abstracts screened, 37 studies were selected, including 34 treatment options for RRMM. Daratumumab, lenalidomide and DEX was found to be the best treatment for RRMM, with the best HR compared to DEX (HR, 0.13; 95% CI, 0.08-0.20; p-score 0.9796). There was no evidence of significant heterogeneity (I2 , 41.3%; p = 0.146). The current NMA confirmed the excellent efficacy of three-drug regimens including anti-CD38 antibodies to treat RRMM and provides background data to evaluate the efficacy of chimeric antigen receptor T-cell treatments and bispecific T-cell engager therapies.
引用
- Minakata D, Fujiwara SI, Yokoyama D, et al. Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies. Br J Haematol. 2023. PMID: 36661264. doi:10.1111/bjh.18654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。